0000000000844088

AUTHOR

Bernard Floccard

showing 2 related works from this author

Proceedings of Réanimation 2017, the French Intensive Care Society International Congress

2017

biologybusiness.industry030208 emergency & critical care medicineLymphocyte proliferationCritical Care and Intensive Care MedicineMeeting Abstractslaw.invention03 medical and health sciencesInterleukin 100302 clinical medicine030228 respiratory systemlawPD-L1ImmunologyPostoperative infectionCardiopulmonary bypassbiology.proteinMedicine030212 general & internal medicinebusinessAnnals of Intensive Care
researchProduct

Icatibant, a New Bradykinin-Receptor Antagonist, in Hereditary Angioedema

2010

BACKGROUND Hereditary angioedema is characterized by recurrent attacks of angioedema of the skin, larynx, and gastrointestinal tract. Bradykinin is the key mediator of symptoms. Icatibant is a selective bradykinin B2 receptor antagonist. METHODS In two double-blind, randomized, multicenter trials, we evaluated the effect of icatibant in patients with hereditary angioedema presenting with cutaneous or abdominal attacks. In the For Angioedema Subcutaneous Treatment (FAST) 1 trial, patients received either icatibant or placebo; in FAST-2, patients received either icatibant or oral tranexamic acid, at a dose of 3 g daily for 2 days. Icatibant was given once, subcutaneously, at a dose of 30 mg. …

medicine.medical_specialtyAngioedemabusiness.industryGeneral MedicinePlacebomedicine.diseaseSurgerylaw.inventionEcallantidechemistry.chemical_compoundRandomized controlled trialchemistrylawIcatibantAnesthesiaHereditary angioedemamedicinemedicine.symptomBradykinin receptorbusinessTranexamic acidmedicine.drugNew England Journal of Medicine
researchProduct